Table: Anges - 6-MTH group results
Aug 9 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Jun 30, 2022 Jun 30, 2021 Dec 31, 2022
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 31 mln 23 mln
(+38.1 pct) (+37.1 pct)
Operating loss 9.12 loss 7.54
Recurring loss 7.42 loss 7.33
Net loss 7.43 loss 7.45
EPS loss 48.51 yen loss 52.70 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001